Literature DB >> 14713378

Academic attainments of children with Down's syndrome: a longitudinal study.

Stephen Turner1, Alison Alborz.   

Abstract

BACKGROUND: Studies of the academic progress of schoolchildren with Down's syndrome have given only limited indication of attainments at different ages. Such normative data, it is argued, could guide professionals and parents in respect to reasonable expectations and typical achievement. AIMS: The aim of the paper is to provide a descriptive account of levels and range of academic attainments reached by a representative sample of children with Down's syndrome over time. SAMPLE: Data relate to 106 children from three studies with the same cohort of families. Mean age was 9.1 years at the first study (1986), 13.7 at the second (1991), and 21.1 at the third (2000). Mean IQ was 40.29.
METHODS: The Academic Attainments Index (AAI) covers reading, writing and numeracy, and was designed for teacher completion. In order to compare attainments to wider norms, scores were compiled by age group, and related to age-specific National Curriculum attainment levels, which are similar to US school grades.
RESULTS: AAI scores were obtained for 102 individuals in 1986, 101 in 1991 and 79 in 2000. Comparisons across age groups indicate that higher scores were achieved by each successive age group up to age 20, and that this pattern held for both more and less able children. Once adjusted for differences in IQ scores between age groups, however, there was some evidence of a levelling off towards the end of the school career. By school-leaving age, the more able children reached at least some National Curriculum Key Stage 2 targets in reading and writing, and some Key Stage 3 targets in number work.
CONCLUSION: Results provide a detailed picture of attainments across ability and age

Entities:  

Mesh:

Year:  2003        PMID: 14713378     DOI: 10.1348/000709903322591244

Source DB:  PubMed          Journal:  Br J Educ Psychol        ISSN: 0007-0998


  7 in total

Review 1.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 2.  On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.

Authors:  Alberto C S Costa
Journal:  Dev Neurosci       Date:  2011-09-02       Impact factor: 2.984

3.  The mouse model of Down syndrome Ts65Dn presents visual deficits as assessed by pattern visual evoked potentials.

Authors:  Jonah Jacob Scott-McKean; Bo Chang; Ronald E Hurd; Steven Nusinowitz; Cecilia Schmidt; Muriel T Davisson; Alberto C S Costa
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-03       Impact factor: 4.799

4.  Development, problem behavior, and quality of life in a population based sample of eight-year-old children with Down syndrome.

Authors:  Helma B M van Gameren-Oosterom; Minne Fekkes; Simone E Buitendijk; Ashna D Mohangoo; Jeanet Bruil; Jacobus P Van Wouwe
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

5.  Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Jonah J Scott-McKean; Adriano L Roque; Krystyna Surewicz; Mark W Johnson; Witold K Surewicz; Alberto C S Costa
Journal:  Neural Plast       Date:  2018-04-10       Impact factor: 3.599

6.  Epidemiology of Birth Defects in Eastern China and the Associated Risk Factors.

Authors:  Qiao-Qiao Wang; Cha-Ying He; Jin Mei; Yi-Lin Xu
Journal:  Med Sci Monit       Date:  2022-01-17

7.  Letter to editor.

Authors:  Faizan Z Kashoo; Mehrunnisha Ahmad
Journal:  J Taibah Univ Med Sci       Date:  2020-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.